Consortium sandbox: Building and sharing resources

Science Translational Medicine

Volumn 6, Issue 242, 2014, Pages

  Lim, Mark D ^a  

^a FasterCures   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUNDING; GOVERNMENT; HEALTH CARE INDUSTRY; HEALTH CARE ORGANIZATION; HUMAN; JOINT VENTURE; MEDICAL RESEARCH; NOTE; PARTICIPATORY MANAGEMENT; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; RESEARCH PRIORITY; RESOURCE ALLOCATION; RESOURCE MANAGEMENT; STANDARDIZATION; COOPERATION; DISEASES;

BIOMEDICAL RESEARCH; COOPERATIVE BEHAVIOR; DISEASE; HUMANS;

EID: 84903762439     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3009024     Document Type: Note

References (31)

1. J. S. Altshuler, E. Balogh, A. D. Barker, S. L. Eck, S. H. Friend, G. S. Ginsburg, R. S. Herbst, S. J. Nass, C. M. Streeter, J. A. Wagner, Opening up to precompetitive collaboration. Sci. Transl. Med. 2, 52cm26 (2010).
2. M. Goldman, Public-private partnerships need honest brokering. Nat. Med. 18, 341 (2012).
3. M. Papadaki, G. Hirsch, Curing consortium fatigue. Sci. Transl. Med. 5, 200fs35 (2013).
4. B. Sidders, C. Brockel, A. Gutteridge, L. Harland, P. G. Jansen, R. McEwen, D. Michalovich, H. Seidel, B. Weiss, B. Williams-Jones, M. Woodwark, Precompetitive activity to address the biological data needs of drug discovery. Nat. Rev. Drug Discov. 13, 83-84 (2014).
5. K. Getz, Transforming R&D through open innovation. Applied Clin. Trials 20, 28-29 (2011).
6. Biomarkers Definitions Working Group, Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
7. W. B. Mattes, E. G. Walker, E. Abadie, F. D. Sistare, J. Vonderscher, J. Woodcock, R. L. Woosley, Research at the interface of industry, academia and regulatory science. Nat. Biotechnol. 28, 432-433 (2010).
8. C. A. Altar, The Biomarkers Consortium: On the critical path of drug discovery. Clin. Pharmacol. Ther. 83, 361-364 (2008).
9. Orphanet, Rare disease database. www.orpha.net/consor/cgi-bin/Disease. php?lng=EN.
10. National Organization for Rare Diseases, Rare diseases database. www.rarediseases.org/rare-disease-information/rare-diseases.
11. R. Bernards, It's diagnostics, stupid. Cell 141, 13-17 (2010).
12. A. D. Barker, C. C. Sigman, G. J. Kelloff, N. M. Hylton, D. A. Berry, L. J. Esserman, I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86, 97-100 (2009).
13. A. Krol, How to accelerate rare disease research? Write a dictionary. Biol.-IT World, 30 Oct 2013.
14. M. Allison, Reinventing clinical trials. Nat. Biotechnol. 30, 41-49 (2012).
15. G. J. Kelloff, C. C. Sigman, Cancer biomarkers: Selecting the right drug for the right patient. Nat. Rev. Drug Discov. 11, 201-214 (2012).
16. M. Tse, P. Kirkpatrick, 2012 in reflection. Nat. Rev. Drug Discov. 12, 8-10 (2013).
17. D. S. Tan, G. V. Thomas, M. D. Garrett, U. Banerji, J. S. de Bono, S. B. Kaye, P. Workman, Biomarker-driven early clinical trials in oncology: A paradigm shift in drug development. Cancer J. 15, 406-420 (2009).
18. A. Maxmen, Translational research: The American way. Nature 478, S16-S18 (2011).
19. E. Vaudano, The innovative medicines initiative: A public private partnership model to foster drug discovery. Comput. Struct. Biotechnol. J. 6, e201303017 (2013).
20. G. Campbell, Statistics in the world of medical devices: The contrast with pharmaceuticals. J. Biopharm. Stat. 18, 4-19 (2008).
21. M. McMurry-Heath, M. A. Hamburg, Creating a space for innovative device development. Sci. Transl. Med. 4, 163fs43 (2012).
22. Sci. Transl. Med. Robotics special issue (2013) http://stm.sciencemag. org/site/misc/robotics-collection.xhtml.
23. Predict-TB Consortium, PreDiCT-TB, and the Critical Path Institute announce partnership to develop effective treatment of TB. www.predict-tb.eu/ predict-tb-and-the-critical-path-institute-announce-partnership-to-develop- effective-treatment-of-tb-read-full-pressrelease.
24. Alzheimer's Association, Groups unite to cross lines between Alzheimer's and Parkinson's. www.alz.org/news-and-events-groups-unite.asp.
25. Foundation for the National Institutes of Health, The FNIH biomarkers consortium launches project to improve diagnosis of kidney injury. www.fnih.org/press/releases/fnih-biomarkers-consortium-launches-project-improve- diagnosis-kidney-injury-0.
26. D. A. Irwin, P. J. Klenow, Sematech: Purpose and performance. Proc. Natl. Acad. Sci. U.S.A. 93, 12739-12742 (1996).
27. C. J. Thomas, J. C. McKew, Playing well with others! Initiating and sustaining successful collaborations between industry, academia and government. Curr. Top. Med. Chem. 14, 291-293 (2014).
28. Observational Medical Outcomes Partnership, Common Data Model. http://omop.org/CDM.
29. J. A. Rogers, D. Polhamus, W. R. Gillespie, K. Ito, K. Romero, R. Qiu, D. Stephenson, M. R. Gastonguay, B. Corrigan, Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: A β regression meta-analysis. J. Pharmacokinet. Pharmacodyn. 39, 479-498 (2012).
30. TransCelerate BioPharma, Risk-based monitoring resources. www.transceleratebiopharmainc.com/rbm-resources.
31. Michael J. Fox Foundation for Parkinson's Research, PPMI database portal. www.ppmi-info.org/access-data-specimens/download-data.